title: Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
abstract: A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1-2% of lung adenocarcinomas (LADCs) in 2012. Several related clinical trials for non-small cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as cabozantinib, lenvatinib, vandetanib, sunitinib, ponatinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of cabozantinib for KIF5B-RET fusion-positive NSCLC are discussed.
authors.affiliation: New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Cheombok-ro, Dong-gu, Daegu, 701-310, Korea. msong@dgmif.re.kr.
authors.forename: Minsoo
authors.initials: M
authors.lastname: Song
authors.affiliation: New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Cheombok-ro, Dong-gu, Daegu, 701-310, Korea. seongheonk@dgmif.re.kr.
authors.forename: Seong-Heon
authors.initials: SH
authors.lastname: Kim
authors.affiliation: New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Cheombok-ro, Dong-gu, Daegu, 701-310, Korea. skyoon@dgmif.re.kr.
authors.forename: Suk Kyoon
authors.initials: SK
authors.lastname: Yoon
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism*; D000077192:Adenocarcinoma of Lung; D000813:Anilides / Q000737:chemistry / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D016547:Kinesins / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D051096:Proto-Oncogene Proteins c-ret / Q000378:metabolism*; D011725:Pyridines / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000813:Anilides; C488101:KIF5B protein, human; D011725:Pyridines; C558660:cabozantinib; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; D016547:Kinesins
keywords: Adenocarcinoma; Cabozantinib; KIF5B-RET; Lung cancer; Non-small cell lung cancer; Small-molecule tyrosine kinase inhibitor